We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Wall Street took notice, and the stock more than doubled in a single session, igniting fresh interest in this under-the-radar biotech. Wall Street was not just impressed, it was outright bullish.

Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death approximately every 9 minutes with over 59,0 ...

Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

Invivyd (IVVD) announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing short and ...

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue reached $13.8 million, marking a 48% growth compared to Q3 2024. Total operating costs and expenses for Q4 2024 were approximately ...

H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...